# Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Canonical URL: https://biopharmsignal.com/news/ATOS/atossa-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-result-51da956e
Ticker: ATOS
Company: Atossa Therapeutics, Inc.
Source: Atossa Therapeutics, Inc.
Published: 2025-03-20 13:13 EST
## Summary

Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time...

## Article Body
Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time

March 20, 2025 09:13 ET | Source: Atossa Therapeutics, Inc.

SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024.

The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com . Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Atossa Therapeutics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at www.atossatherapeutics.com .

About Atossa Therapeutics Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company’s lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including metastatic, neoadjuvant, adjuvant, and prevention settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com .

Contact Michael Parks, VP Investor and Public Relations 484-356-7105 michael.parks@atossainc.com
## Recent Company News
- 2025-09-17 12:00 EST — [Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-appoints-core-ir-for-investor-relations-shareholder-communic-7dbf6e27) — Source: Atossa Therapeutics, Inc.
- 2025-04-30 12:45 EST — [Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-issuance-of-u-s-patent-no-12-281-056-including-58--540af8e3) — Source: Atossa Therapeutics, Inc.
- 2025-04-29 12:45 EST — [Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-proposes-potentially-groundbreaking-study-aimed-at-reducing--15eb7318) — Source: Atossa Therapeutics, Inc.
- 2025-03-25 12:00 EST — [Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-full-year-2024-financial-results-and-provides-corp-d35fa88f) — Source: Atossa Therapeutics, Inc.
- 2025-03-20 13:13 EST — [Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-result-51da956e) — Source: Atossa Therapeutics, Inc.
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)